Find Drugs for Infections and Infectious Diseases in Phase III Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothA partner for the pharma and biotech industries to improve patient outcomes & quality of life

            Contact the Supplier

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 03, 2020

            Details:

            AMRI has been chosen to contribute to the supply of the vaccine candidate through sterile fill/finish of AZD1222 at AMRI’s drug product manufacturing facility in Albuquerque, New Mexico.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 20-valent pneumococcal conjugate vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: PF-06482077

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 22, 2020

            Details:

            Two studies of the 20-valent pneumococcal polysaccharide conjugate vaccine candidate, 20vPnC, evaluating a four-dose series in infants starting at 2 months of age.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 20-valent pneumococcal conjugate vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 14, 2020

            Details:

            In this study the 20vPnC safety profile was similar to the Prevnar 13® (pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) control group.